tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Sihuan Pharmaceutical’s Semaglutide Injection NDA Accepted by NMPA

Story Highlights
  • Sihuan Pharmaceutical’s subsidiary’s NDA for Semaglutide Injection was accepted by NMPA.
  • This milestone enhances Sihuan’s competitive position in diabetes treatment market.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Sihuan Pharmaceutical’s Semaglutide Injection NDA Accepted by NMPA

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Sihuan Pharmaceutical Holdings Group ( (HK:0460) ) has shared an update.

Sihuan Pharmaceutical Holdings Group announced that its subsidiary, Huisheng Biopharmaceutical, has had its new drug application for Semaglutide Injection accepted by the National Medical Products Administration. This development marks a significant milestone in the company’s R&D efforts in diabetes treatment, potentially enhancing its competitive position in the market. With diabetes being a major focus area, the acceptance of Semaglutide Injection, a GLP-1 receptor agonist, underscores Huisheng’s commitment to expanding its diabetes treatment portfolio and addressing the growing diabetes prevalence in China.

More about Sihuan Pharmaceutical Holdings Group

Sihuan Pharmaceutical Holdings Group, founded in 2001 and listed on the Hong Kong Stock Exchange in 2010, is an international company specializing in medical aesthetics and pharmaceuticals. With a focus on innovation, it boasts a strong R&D platform, a diverse global product pipeline, and efficient production capabilities. Huisheng Biopharmaceutical, a subsidiary, is dedicated to diabetes treatment, offering a comprehensive range of products and integrated solutions for diabetic patients.

Average Trading Volume: 135,457,290

Technical Sentiment Signal: Buy

Current Market Cap: HK$13.16B

See more data about 0460 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1